Tuesday , May 17 2022

Women with Allergan breast implants may challenge them for Cancer cancer


A group of more than 200 women considers legal action over the controversial breast implants that have been linked to a rare type of cancer.

The women claim that they had not had enough information about the risks of Textile allergens implants, which were withdrawn from the European market in December. Six of the women developed large cell anemiale lymphoma (ALCL), rare blood cancer that has linked to texture implants.

Irene Kennedy, 49, was diagnosed with ALCL in December, eight years after being implanted. "I had not heard of it, I did not know anything about it at all," said Kennedy, who lives in Leeds. "It's very scary."

Since then Kennedy has its implants and crawling tissue around, which usually leads to full recovery without the need of chemotherapy. But he is still concerned about the possibility of the cancer returning and wanting to see greater awareness of the risks associated with breast implants.

"If someone was saying, By the way, you could get cancer, your ears would disappear and it would be more a thoughtful process that you would do, "he said.

Three women who have been given legal steps to the implants have been given after having preventative mastectomens to protect against high genetic risk of breast cancer and now fear that they may be at greater risk of getting different cancer

Others in the group have had different complications, such as capsule contracture, where tissue and breastfeeding are hardened around the implant, or say they were not warned about the connection with ALCL, which the UK regulator warned for doctors first in 2011. The implants were withdrawn from the market last year.

Sarah Moore, a lawsuit at Leigh Day's legal firm, investigating a possible group claim for women, said many women said they did not receive a warning or insufficient warning about the risk from developing ALCL and whether they had been fully informed that they would never have chosen to have these procedures.

"There are many [them] incredibly angry that choosing a procedure intends to improve self-esteem and well-being that they have been exposed to the risk of developing a type of cancer that could be a threat to life, and that it can be completely avoided, "he said .

"Many of these women have a family history of cancer and therefore they were hyper-alert to information about cancer risk, no matter how rare," Moore said.

The figures collected by plastic surgeons suggested that there were at least 615 cases of the disease associated with breast implants and 16 deaths in the world. In the UK, where general textile implants have been favored by surgeons, there were 45 positive cases of lymphoma, and one death. The health regulator estimated the risk in one in 24,000 women with implants.

The cancer forms in the raw capsule around the implant and usually starts with pain and breast inflammation. Women with the implants and capsules that have been abolished may have full recovery, but if not treated, the disease can spread through the body and become a life threat.

Last year, the Association of British Plastic Plastic Surgeons (Baaps) said its members to use Allergan implants as precautions, but said that the scientific data did not suggest the need to eliminate or exchang any existing implants. The French regulatory renewal agency rejected a CE mark for Allergan's web-based intervention in December but the company said that he is currently working with the manager to renew his approval to market the product.

In a statement, Allergan said that the company was committed to fully comply with all regulatory requirements and rigorous scientific evidence.

The company added: "Allergan's top priorities are" Patient safety and product quality. Allergan continues to stand firmly behind the benefit / risk profile of its breast implant products, including texture breast implants. texture implants – based on scientific evidence – persistent and positive. "

The health regulator, the Medicines and Healthcare Products Regulatory Agency, who recently issued guidance on ALCL and breast implants, said that women with Allergan ulcers implants did not need to be removed or had any additional clinical sequence.

"MHRA has worked closely with clinical stakeholders to raise awareness of this rare disease," he said in a statement.

Source link